Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313299 · ClinicalTrials.gov registry record · Phase 3
Dysport® Adult Upper Limb Spasticity
A Phase 3 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 3
- Development phase
- 243
- Enrollment target
NCT01313299 is a Phase 3 study that has completed, run by Ipsen. The registered enrollment target is 243 participants.
The verdict
NCT01313299, a Phase 3 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 243 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess the efficacy of Dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.
Interventions
- DRUG Placebo
- BIOLOGICAL Botulinum toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313299
The ClinicalTrials.gov registry entry for NCT01313299 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01313299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313299 about?
NCT01313299 is a clinical study titled "Dysport® Adult Upper Limb Spasticity". The purpose of this research study is to assess the efficacy of Dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.
What is the current status of trial NCT01313299?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 243 participants. The study started on 2011-08. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01313299?
The interventions under investigation include: Placebo (DRUG), Botulinum toxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01313299?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.